<DOC>
	<DOCNO>NCT00936832</DOCNO>
	<brief_summary>RATIONALE : Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , irinotecan hydrochloride , leucovorin calcium , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together sunitinib malate may kill tumor cell . PURPOSE : This phase II trial study well give sunitinib malate together combination chemotherapy work front-line therapy treat patient metastatic rectal cancer remove surgery .</brief_summary>
	<brief_title>Sunitinib Malate Combination Chemotherapy Front-Line Therapy Treating Patients With Metastatic Rectal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluation efficacy front-line treatment sunitinib malate FOLFIRI chemotherapy 3 month patient rectal cancer synchronous metastasis deem unresectable multidisciplinary consultation . Secondary - Evaluate rate resection secondary metastasis rectal cancer , rate R0 resection metastasis rectal cancer , rate complete response resection . - Evaluate rate local failure ( progression rectal cancer ) . - Evaluate rate local complication . - Evaluate disease-free survival . - Evaluate progression-free survival , metastatic progression-free survival , local progression-free survival . - Evaluate symptom-free survival . - Evaluate overall survival . - Evaluate quality life , specifically fatigue global health score ( EORTC QLQ-C30 ) . - Evaluate tolerance treatment . - Conduct translational research , particular , pharmacokinetic study plasma rectal tumor biopsy , histological molecular study . OUTLINE : Patients receive simplify FOLFIRI chemotherapy comprise irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , fluorouracil IV 46 hour day 1 , 15 , 29 . Patients also receive oral sunitinib malate daily day 1-28 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients may undergo surgical resection and/or local radiotherapy tumor regress . After resection radiotherapy , patient may undergo 4 course study treatment . Biopsies tumor healthy mucosa collect translational research baseline . Blood sample collect pharmacodynamic pharmacogenetic study baseline week 6 . Patients also complete quality-of-life questionnaire ( EORTC QLQ-C30 ) baseline periodically thereafter . After completion study therapy , patient follow every 12 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum Lower pole tumor &lt; 12 cm anal margin Synchronous metastases liver and/or lung Unresectable resectability uncertain accord decision local multidisciplinary consultation Lesions measurable 1 dimension RECIST criterion ( metastasis primary rectal cancer ) No rectal obstruction require surgery emergency fit prosthesis No CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine clearance ≥ 60 mL/min Hemoglobin ≥ 10 g/dL ( transfusion allow ) FEV ≥ 50 % QT interval ≤ 450 m ( men ) ≤ 470 m ( woman ) Total bilirubin ≤ 1.5 time upper limit normal Serum albumin ≥ 25 g/L Not pregnant nursing Fertile patient must use effective contraception No history another cancer except nonmelanoma skin cancer curatively treat carcinoma situ cervix History cancer allow provided patient diseasefree &gt; 3 year None following : Congestive heart failure coronary heart disease Myocardial infarction within past year Uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) despite optimal medical management No active severe rectal bleed No liver failure No known Gilbert syndrome No severe uncontrolled infection No chronic diarrhea , malabsorption syndrome , intestinal obstruction/subocclusion No severe uncontrolled pain ( visual analogue scale 5/10 ) morphine treatment No medical , psychological , social condition , investigator 's opinion , could affect patient 's compliance study treatment No hypersensitivity component study treatment PRIOR CONCURRENT THERAPY : See Patient Characteristics No prior radiotherapy pelvis More 4 week since prior experimental therapy More 7 day since prior CYP3A4 inhibitor administration sunitinib malate More 12 day since prior CYP3A4 inducer No concurrent participation another clinical study No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>lung metastasis</keyword>
</DOC>